Register
FDA allows marketing of first rapid diagnostic test for detecting Ebola virus antigens |
Clinical News
eMediNexus Coverage from: 
FDA allows marketing of first rapid diagnostic test for detecting Ebola virus antigens
eMediNexus,  13 October 2019
remove_red_eye 472 Views
#Critical Care #Emergency Medicine #Pathology and Lab Medicine #Public Health

0 Read Comments                

The U.S. Food and Drug Administration has allowed marketing of a rapid diagnostic test (RDT) to detect Ebola virus antigens (proteins) in human blood from certain living individuals and samples from certain recently deceased individuals suspected to have died from Ebola (cadaveric oral fluid). The OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test the FDA has allowed to be marketed in the U.S. for the Ebola Virus Disease (EVD). The test provides a rapid, presumptive diagnosis that must be confirmed… (FDA, October 10, 2019)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now